Physician profile
Gavin Whapshare
NPI 1003171901
$6,856.91
in general payments reported to CMS, 2019-2025
39 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $245 · 2021: $32.83 · 2022: $179 · 2023: $1,386 · 2024: $1,828 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.89 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,055.55 | 2019-2025 | |
| Abbvie INC. | $897.78 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $596.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $568.17 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $512.25 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $451.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $345.86 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.77 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $273.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $271.45 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.61 | 2019-2025 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $160.37 | 2019-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Bayer Healthcare Pharmaceuticals INC. | $154.72 | 2024-2025 | |
| Exact Sciences Corporation | $108.05 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $99.46 | 2019-2025 | Zoryve |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Whapshare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.